NewsSource: EClinCloud

Company Overview | EClinCloud

3 min readEClinCloud Editorial Team
Article image

Source: EClinCloud. Author: EClinCloud.

ECC

EClinCloud

EClinCloud (Shenzhen) Technology Co., Ltd. (referred to as EClinCloud) is a healthcare and life-sciences technology company based in China and serving the world. With the mission of "bringing effective treatments to patients through technological innovation," it is driven by science and medicine to combine digital technology with life-sciences data, build an end-to-end digital clinical trial cloud platform, and provide technical solutions for clinical endpoint assessment, helping domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.

Article image

Article image

EClinCloud provides a one-stop clinical endpoint assessment solution, helping standardize clinical trial endpoint data, improve data credibility and reliability, and thereby increase the success rate of bringing drugs to market.

The solutions mainly include scale management, rater training, electronic clinical outcome assessment system (eCOA), central reading, and more.





Article image

The platform mainly includes the electronic clinical outcome assessment system (eCOA), clinical trial management system (CTMS), clinical trial master file management system (eTMF), electronic data capture system (EDC), randomization and trial supply management system (RTSM), resource management system (RM), device transit system (MAMS), and more.

EClinCloud's integrated SaaS cloud platform breaks down data silos by unifying previously standalone systems, enabling data interoperability across systems, reducing duplicate data entry and cumbersome document management, maximizing the platform's digital value, and accelerating clinical research.





Article image

Supported by the integrated application of cutting-edge digital technologies such as big data, artificial intelligence, and cloud computing, EClinCloud applies an innovative "technology + data + industry" model to develop intelligent tools that empower the digital transformation of clinical trials, which will further reduce labor and time costs and improve efficiency.





Article image

Our Team


Article image


EClinCloud is headquartered in the core of the Guangdong-Hong Kong-Macao Greater Bay Area—Shenzhen Bay Science and Technology Ecological Park—with its clinical and medical center in Beijing, business center in Shanghai, R&D center in Chengdu, and international business development in New Jersey, USA.


EClinCloud's core team has over 16 years of experience in new drug R&D. The company currently has more than 120 experienced employees, primarily consisting of business leaders with a global perspective, opinion leaders in precision medicine evaluation for clinical research, SaaS cloud platform technical experts, and technological innovators. At the same time, we are expanding our global footprint and continuously bringing in industry professionals from well-known domestic and international pharmaceutical companies, CROs, hospitals, and leading technology companies.



Article image





About EClinCloud

EClinCloud is a technology company focused on clinical R&D. It provides an integrated, interoperable, all-in-one clinical trial cloud platform (including technology products such as eCOA, CTMS, eTMF, EDC, and RTSM, along with solutions such as scale management, linguistic validation, rater training, and data quality analysis) as well as clinical trial endpoint assessment technologies across therapeutic areas (including oncology, central nervous system, ophthalmology, and others). By combining cutting-edge technology with life-sciences data to build a globally leading, patient-centric SaaS cloud platform for clinical evidence support, it helps domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.




Article image


Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.